Get the Stockscreener App
5.87
6.34%
+0.35
ClearPoint Neuro Inc stock is currently priced at $5.87, with a 24-hour trading volume of 73,681.
It has seen a +6.34% increased in the last 24 hours and a -11.06% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $5.48 pivot point. If it approaches the $5.78 resistance level, significant changes may occur.
Previous Close:
$5.52
Open:
$5.59
24h Volume:
73,681
Market Cap:
$158.90M
Revenue:
$23.96M
Net Income/Loss:
$-22.09M
P/E Ratio:
-6.9059
EPS:
-0.85
Net Cash Flow:
$-14.77M
1W Performance:
+11.60%
1M Performance:
-11.06%
6M Performance:
-3.77%
1Y Performance:
-37.15%
1D Range:
$5.59
$5.88
52W Range:
$4.05
$9.87
ClearPoint Neuro Inc Stock (CLPT) Company Profile
Name
ClearPoint Neuro Inc
Sector
Industry
Phone
949 900 6833
Address
5 Musick, Irvine, CA
ClearPoint Neuro Inc Stock (CLPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-16-23 | Resumed | B. Riley Securities | Buy |
| Apr-05-22 | Resumed | B. Riley Securities | Buy |
| Mar-18-21 | Initiated | Lake Street | Buy |
| Jul-17-20 | Initiated | B. Riley FBR | Buy |
ClearPoint Neuro Inc Stock (CLPT) Latest News
Rapid Micro Biosystems, Inc. (RPID) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
Tandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
ClearPoint Neuro feliciteert partner AviadoBio met de behandeling van de eerste patiënt in klinisch onderzoek ASPIRE-FTD, waarin AVB-101 wordt geëvalueerd voor frontotemporale dementie met GRN-mutaties
GlobeNewswire Inc.
ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
GlobeNewswire Inc.
Why ClearPoint Neuro (CLPT) Stock Might be a Great Pick
Zacks Investment Research
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency
GlobeNewswire Inc.
ClearPoint Neuro Inc Stock (CLPT) Financials Data
ClearPoint Neuro Inc (CLPT) Revenue 2024
CLPT reported a revenue (TTM) of $23.95 million for the quarter ending December 31, 2023, a +16.56% rise year-over-year.
ClearPoint Neuro Inc (CLPT) Net Income 2024
CLPT net income (TTM) was -$22.09 million for the quarter ending December 31, 2023, a -34.40% decrease year-over-year.
ClearPoint Neuro Inc (CLPT) Cash Flow 2024
CLPT recorded a free cash flow (TTM) of -$14.77 million for the quarter ending December 31, 2023, a +14.68% increase year-over-year.
ClearPoint Neuro Inc (CLPT) Earnings per Share 2024
CLPT earnings per share (TTM) was -$0.91 for the quarter ending December 31, 2023, a -33.82% decline year-over-year.
ClearPoint Neuro Inc Stock (CLPT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SABRA MAZIN | Chief Operating Officer |
Mar 06 '24 |
Option Exercise |
0.00 |
6,913 |
0 |
47,352 |
| BURNETT JOSEPH MICHAEL | CEO and President |
Mar 06 '24 |
Option Exercise |
0.00 |
23,704 |
0 |
274,430 |
| D'Alessandro Danilo | Chief Financial Officer |
Mar 06 '24 |
Option Exercise |
0.00 |
9,383 |
0 |
58,312 |
About ClearPoint Neuro Inc
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system, a neuro-navigation system designed for insertion of catheters, electrodes, and laser fibers to treat various neurological diseases and conditions, as well as for performing biopsies. In addition, the company's product pipeline includes ClearTrace system, a product candidate designed to allow catheter-based minimally invasive procedures in the heart to be performed in an MRI suite. The company has a license agreements with The Johns Hopkins University; development agreement with Mayo Clinic to design and develop MRI-guided therapies for stroke; and a collaborative license and co-development agreement with Clinical Laserthermia Systems AB. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was founded in 1998 and is headquartered in Irvine, California.
0.77%
Cap:
|
Volume (24h):